BD (Becton, Dickinson and Co.) announced a collaboration June 13 with a Mayo Clinic platform that will give the Franklin Lakes medical company access to real-world data, providing deeper insights into what patients need.
The collaboration gives BD to access de-identified patient data – which means individuals’ identities are protected – from Mayo Clinic Platform_Discover. This platform includes data sets from 10 million patients, including both structured and unstructured data, images, 1.2 billion lab test results, 3 million echocardiograms and more than 640 million clinical notes, according to the announcement.
Using data mining, next generation artificial intelligence and machine learning, BD will analyze this data “to perform detailed post-market surveillance on its products to fuel innovation and unlock a faster, more efficient path to market, with the ultimate goal of improving patient care,” the company said.
Lisa Boyle, vice president of global clinical affairs and medical affairs strategy for BD, said in a statement that randomized control trials have been the “gold standard” in testing medical devices.
But to truly understand whether medical companies such as BD are meeting patients’ needs, “[w]e need to be leveraging real-world evidence, using datasets like those from Mayo Clinic Platform, to understand the many parameters that we wouldn’t normally capture in a clinical trial and understand patients’ care pathways and address the needs of diverse patients …”
Steven Bethke, vice president for product portfolio, Mayo Clinic Platform, added, “Mayo Clinic Platform_Discover enables medical technology leaders such as BD to derive key insights as they develop solutions for their customers and patients as quickly and safely as possible.”
